Unfit individuals even have the alternative of venetoclax in addition obinutuzumab (VO) as frontline therapy. This is predicated with a period III trial that compared VO with ClbO in aged/unfit sufferers.113 VO was remarkable with regards to reaction charge and progression-cost-free survival, and had a comparable safety profile. Within this trial V